Opinion|Videos|April 3, 2025
Interdisciplinary Approaches to Breast Cancer Care and ADC Treatment Barriers Due to Social Determinants of Health
Panelists discuss how optimizing antibody-drug conjugate (ADC) therapy in patients with metastatic breast cancer (mBC) requires interdisciplinary care, including oncologists, pharmacists, and nurses. Adherence barriers such as cost, access, and insurance are addressed via financial and social support.
Advertisement
Video content above has been prompted by the following:
- What interdisciplinary approaches to care can help optimize ADC therapy outcomes in patients with mBC?
- Do patients receiving ADC therapy at your practice experience adherence barriers due to social determinants of health, treatment costs, accessibility, or insurance coverage?
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Related Articles
- Understanding the Risk of Second Primary Cancers After Early Breast Cancer
September 16th 2025
- Encouraging Successful Completion of the Shingles Vaccine Series
September 16th 2025
- A Pharmacist’s View of Emerging CML Treatment
September 4th 2025
- Potential for Precision: Exploring Targeted Therapies in mCRC Care
September 4th 2025
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times - Pharmacy Practice News and Expert Insights
1
Subcutaneous Formulation of Guselkumab Receives FDA Approval in Ulcerative Colitis
2
FDA Grants Accelerated Approval to Elamipretide, First Treatment for Barth Syndrome
3
Confronting the Mental Health Crisis: Structural Inequities, Market Pressures, and the Role of Pharmacy Solutions
4
Belatamab Mafodotin Triplet Improved Survival, Responses in Patients Refractory to Lenalidomide
5